<DOC>
	<DOCNO>NCT02690922</DOCNO>
	<brief_summary>The aim study improve major molecular remission ( MMR ) rate reduce cost treat ph ( + ) Acute Lymphoblastic Leukemia ( ALL ) adjust chemotherapy regimen dosage Tyrosine Kinase Inhibitor ( TKI ) . low classification chemotherapy drug , low side effect bring would grateful news patient regimens gain successful result , also final aim effort .</brief_summary>
	<brief_title>Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor Treat ph+ Acute Lymphoblastic Leukemia Patients</brief_title>
	<detailed_description>The investigator new therapy regimen : The investigator use dexamethasone 10mg/d ( d3-d7 ) pre-processing therapy , dasatinib 100mg ( d1-d84 ) plus prednisone 60mg/m2 ( d1-24 ) , reduce d32 , inductive treatment inductive treatment , patient get major molecular remission , patient get consolidation therapy , methotrexate ( MTX ) 3g/m2 d1 , , patient would exclude trail . consolidation therapy , patient match bone marrow donor , investigator suggest patient receipt allogens-stem cell transplantation , otherwise , autogens stem cell transplantation also consider patient applicable bone marrow donor . side , patient still get MMR two cycle , maybe patient try Car-T , chemotherapy regimen .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Get sign informed consent patient family member 2 . Age â‰¥ 18 one full year life 3 . Confirm ph + ALL molecular biology level 4 . Normal heart lungs function 5 . Normal liver kidney function 1 . Leukemia nervous system 2 . Recurrent patient 3 . Allergies associate drug research 4 . At time organ ' malignant tumours 5. participate clinical research time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>